Abstract
We investigated the feasibility/efficacy of oxaliplatin in combination with trastuzumab as first-/second-line treatment of HER2-positive metastatic breast cancer (MBC). Patients received oxaliplatin/trastuzumab every 21 days and were evaluated every 6 weeks using RECIST criteria. The study closed early due to slow accrual. Twenty-five patients were evaluable; of these, 5 (20%) had objective responses to oxaliplatin/trastuzumab. Therapy was well tolerated (no grade-4 and gastrointestinal grade-3 toxicity in 4% of patients), but had only modest activity (median time-to-progression 1.8 months). Substitution of oxaliplatin for cisplatin or carboplatin, in combination with trastuzumab, does not appear to improve first-/second-line therapy in HER2-positive MBC.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal / toxicity
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents / toxicity
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Humans
-
Middle Aged
-
Neoplasm Metastasis
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / therapeutic use*
-
Organoplatinum Compounds / toxicity
-
Oxaliplatin
-
Patient Selection
-
Receptor, ErbB-2 / genetics*
-
Trastuzumab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Oxaliplatin
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
Trastuzumab